|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 在经历 transcatheter 的病人的 atrial 纤维性颤动的临床、预示的含意大动脉的阀门培植显示文摘 AIM: To study a cohort of consecutive patients under-going transcatheter aortic valve implantation (TAVI) and compare the outcomes of atrial fibrillation (AF) patients vs patients in sinus rhythm (SR). METHODS: All consecutive patients undergoing TAVI in our hospital were included. The AF group comprised patients in AF at the time of TAVI or with history of AF, and were compared with the SR group. Procedural, echocardiographic and follow-up variables were compared. Likewise, the CHA 2 DS 2-VASC stroke risk score and HAS-BLED bleeding risk score and antithrombotic treatment at discharge in AF patients were compared with that in SR patients. RESULTS: From a total of 34 patients undergoing TAVI, 17 (50%) were allocated to the AF group, of whom 15 (88%) were under chronic oral anticoagulation. Patients in the AF group were similar to those in the SR group except for a trend (P = 0.07) for a higher logistic EuroSCORE (28% vs 19%), and a higher prevalence of hypertension (82% vs 53%) and chronic renal failure (17% vs 0%). Risk of both stroke and bleeding was high in the AF group (mean CHA 2 DS 2-VASC 4.3, mean HAS-BLED 2.9). In the AF group, treatment at discharge included chronic oral anticoagulation in all except one case, and in association with an antiplatelet drug in 57% of patients. During a mean follow-up of 11 mo (maximum 32), there were only two strokes, none of them during the peri-procedural period: one in the AF group at 30 mo and one in the SR group at 3 mo. There were no statistical differences in procedural success, and clinical outcome (survival at 1 year 81% vs 74% in AF and SR groups, respectively, P = NS). CONCLUSION: Patients in AF undergoing TAVI show a trend to a higher surgical risk. However, in our cohort, patients in AF did not have a higher stroke rate compared to the SR group, and the prognosis was similar in both groups. | Pablo Salinas Raúl Moreno Luis Calvo Santiago Jiménez-Valero Guillermo Galeote Angel Sánchez-Recalde Teresa López-Fernández Sergio Garcia-Blas Diego Iglesias Luis Riera Isidro Moreno-Gómez Jose María Mesa Ignacio Plaza Rocio Ayala Rosa Gonzalez José-Luis López-Sendón | 2012 | World Journal of Cardiology2012，4，1： | 2 |
| 2 | Dehy - droepiandrosterone: Aninexpen sive steroid hormone that decreases the mortality due to sepsisfollowing trauma - in duced hemorrhage显示文摘 | Angele MK Catania RA Ayala A | 1998 | Archives of Surgery1998，133，12： | 1 |
| 3 | Dehydroepiardrosterone restores immune function following trauma-haemtrhage by a direot effect on T lymphocytes显示文摘 | Catania RA Angele NK Ayala A | 1999 | Ctokine1999，11，6： | 1 |
| 4 | Dehy 2droepi and ros- terone: an inexpensive steroid hormone that decreases the mortality due to sepsis following trauma-induced hemorrhage 显示文摘 | Angele MK Catania RA Ayala A | 1998 | Arch surg1998，133，12： | 1 |
| 5 | The amygdala regulates the antianxiety sensitization effect of flumazenil during repeated chronic ethanol or repeated stress显示文摘 | Knapp DJ Overstreet DH Angel RA | 2007 | Alcohol Clin Exp Res2007，31，： | 1 |
| 6 | Liver failure and defective hepatocyte, regeneration in interleukin-6-deficient mice 显示文摘 | Cressman DE Greenbaum DE Angels RA | 1996 | Science1996，274，5291： | 1 |
| 7 | Immunomodulatory Effects of Dehydroepiandrosterone in Proestrus Female Mice After Trauma - hemorrhage 显示文摘 | Knoferl MW Angele MK Catania RA | 2003 | J Appl Physiol2003，95，2： | 1 |
| 8 | Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period显示文摘 | Raúl J. Andrade M. Isabel Lucena M. Carmen Fernández Gloria Pelaez Ketevan Pachkoria Elena García-Ruiz Beatriz García-Mu?oz Rocio González-Grande Angeles Pizarro José Antonio Durán Manuel Jiménez Luis Rodrigo Manuel Romero-Gomez José María Navarro Ramón P | 2005 | Gastroenterology2005，，2： | 1 |
| 9 | Immunomodulatory effects of dehydroepiandrosterone in proestrus female mice after trauma-hemorrhage显示文摘 | Knoferl MW Angele MK Catania RA | 2003 | J Appl Physiol2003，95，2： | 1 |
| 10 | Dehydroepiandrosterone restores immune function following trauma-haemorrhage by a direct effect on Tlymphocytes显示文摘 | Catania RA Angele NK Ayala A | 1999 | Cytokine1999，11，6： | 1 |
| 11 | L-arginine:a unique amino acid for improving depressed wound immune function following hemorrhage显示文摘 | ANGELE MK NITCH SM HATZ RA | 2002 | Eur Surg Res2002，34，12： | 1 |
| 12 | Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period显示文摘 | Raúl J. Andrade M. Isabel Lucena M. Carmen Fernández Gloria Pelaez Ketevan Pachkoria Elena García-Ruiz Beatriz García-Mu?oz Rocio González-Grande Angeles Pizarro José Antonio Durán Manuel Jiménez Luis Rodrigo Manuel Romero-Gomez José María Navarro Ramón P | 2005 | Gastroenterology2005，，2： | 1 |
| 13 | An information architecture for a performance management framework by collaborating SMEs显示文摘 | Juan José Alfaro Saiz Raúl Rodríguez Rodriguez Angel Ortiz Bas | 2010 | Computers in Industry2010，61，7： | 1 |
| 14 | Immunomodulatory effects of dehydroepiandrosterone in proestrus female mice after trauma-hemorrhage显示文摘 | Knoferl MW Angele MK Catania RA | 2003 | J Appl Physiol2003，95，2： | 1 |
| 15 | Nasal NK/T-cell lymphoma with disseminated disease treated with aggressive combined therapy显示文摘 | Agustin Avilés M.D. Natividad Neri Raúl Fernández Angel Calva Judith Huerta-Guzmán M. Jesús Nambo | 2003 | Medical Oncology2003，，1： | 1 |
| 16 | Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar(CT-P13)in patients with inflammatory bowel disease显示文摘BACKGROUND Infliximab original has changed the natural history of inflammatory bowel diseases(IBD) over the past two decades. However, the recent expiration of its patent has allowed the entry of the first Infliximab biosimilar into the European and Spanish markets. Currently switching drugs data in IBD are limited. AIM To compare the efficacy of infliximab biosimilar, CT-P13, against infliximab original, analyzing the loss of response of both at the 12 mo follow-up in patients with IBD.METHODS An observational study of two cohorts has been conducted. One retrospective cohort that included patients with IBD treated with Infliximab original, and a prospective cohort of patients who were switching from infliximab original to infliximab biosimilar(CT-P13). We had analyzed the overall efficacy and loss of efficacy in patients in remission at the end of one year after treatment with the original drug compared to the results of the year of treatment with the biosimilar.RESULTS98 patients(CD 67, CU 31) were included in both cohorts. The overall efficacy for infliximab original per year of treatment was 71% vs 68.2% for infliximab biosimilar(P = 0.80). The loss of overall efficacy at 12 mo for infliximab original was 6.6% vs 14.5% for infliximab biosimilar(P = 0.806). The loss of efficacy in patients who were in basal remission was 16.3% for infliximab original vs 27.1% for infliximab biosimilar. Adverse events were 9.2% for infliximab original vs 11.2% for infliximab biosimilar. CONCLUSION The overall efficacy and loss of treatment response with infliximab biosimilar(CT-P13) is similar to that observed with infliximab original in patients who were switching at the 12 mo follow-up. There is no difference in the rate of adverse events. | María Fernanda Guerra Veloz Federico Argüelles-Arias Luisa Castro Laria Belén Maldonado Pérez Antonio Benítez Roldan Raúl Perea Amarillo Vicente Merino Bohórquez Miguel Angel Calleja Angel Caunedo Alvarez Angel Vilches Arenas | 2018 | World Journal of Gastroenterology2018，24，46： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员